Terbutaline and the Prevention of Nocturnal Hypoglycemia in Type 1 Diabetes

OBJECTIVE—Bedtime administration of 5.0 mg of the β(2)-adrenergic agonist terbutaline prevents nocturnal hypoglycemia but causes morning hyperglycemia in type 1 diabetes. We tested the hypothesis that 2.5 mg terbutaline prevents nocturnal hypoglycemia without causing morning hyperglycemia. RESEARCH...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooperberg, Benjamin A., Breckenridge, Suzanne M., Arbelaez, Ana Maria, Cryer, Philip E.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2008
Materias:
Clinical Care/Education/Nutrition/Psychosocial Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584177/
https://www.ncbi.nlm.nih.gov/pubmed/18782903
http://dx.doi.org/10.2337/dc08-0520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584177/
https://www.ncbi.nlm.nih.gov/pubmed/18782903
http://dx.doi.org/10.2337/dc08-0520

Ejemplares similares